Jasper Therapeutics (JSPR) Non-Current Assets (2019 - 2026)

Jasper Therapeutics has reported Non-Current Assets for 8 years, with the latest figure at $231000.0 in Q2 2026.

• On a quarterly basis, Non-Current Assets fell 93.4% year-over-year to $231000.0 in Q2 2026; TTM through Jun 2026 was $7.8 million, a 53.24% decrease from a year earlier, with the FY2025 full-year figure at $1.1 million, down 72.26% from the prior year.
• Non-Current Assets was $231000.0 for Q2 2026 at Jasper Therapeutics, down from $1.1 million in the prior quarter.
• The five-year high for Non-Current Assets was $7.1 million in Q2 2022, with the low at $231000.0 in Q2 2026.
• Average Non-Current Assets over 5 years is $4.8 million, with a median of $5.2 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: Non-Current Assets jumped 39.39% in 2022, then plunged 93.4% in 2026.
• Over 5 years, Non-Current Assets stood at $6.6 million in 2022, then slipped by 10.2% to $6.0 million in 2023, then slumped by 31.34% to $4.1 million in 2024, then slumped by 72.26% to $1.1 million in 2025, then plunged by 79.63% to $231000.0 in 2026.
• The last three Non-Current Assets figures came in at $231000.0 (Q2 2026), $1.1 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.